Cardiff Oncology, Inc. (CRDF)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250K 500K 750K Q3 '21: 345K Q4 '21: 359K Q1 '22: 361K Q2 '22: 384K Q3 '22: 391K Q4 '22: 386K Q1 '23: 395K Q2 '23: 412K Q3 '23: 460K Q4 '23: 488K Q1 '24: 610K Q2 '24: 665K Q3 '24: 689K Q4 '24: 684K Q1 '25: 588K Q2 '25: 546K Q3 '25: 501K Q4 '25: 593K Q1 '26: 525K Q2 '26: 508K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q2 '15: 17.6K Q3 '15: -155.8K Q4 '15: -316.5K Q1 '16: -455.9K Q2 '16: -731.3K Q3 '16: -950.5K Q4 '16: -1.3M Q1 '17: -1.7M Q2 '17: -1.6M Q3 '17: -1.6M Q4 '17: -1.3M Q1 '18: -1.1M Q2 '18: -907.3K Q3 '18: -495.7K Q4 '18: -219.1K Q1 '19: 109.1K Q2 '19: 238.6K Q3 '19: 228.6K Q4 '19: 243.1K Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -25.8M Q4 '21: -28.9M Q1 '22: -34.5M Q2 '22: -38M Q3 '22: -40M Q4 '22: -39.9M Q1 '23: -40.9M Q2 '23: -42.6M Q3 '23: -44.5M Q4 '23: -45.4M Q1 '24: -44.3M Q2 '24: -44.6M Q3 '24: -46.4M Q4 '24: -48.7M Q1 '25: -52.1M Q2 '25: -54.3M Q3 '25: -53.7M Q4 '25: -49M Q1 '26: -47.4M Q2 '26: -42.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -25.4M Q4 '21: -28.3M Q1 '22: -34.1M Q2 '22: -37.8M Q3 '22: -39.4M Q4 '22: -38.7M Q1 '23: -38.9M Q2 '23: -39.6M Q3 '23: -40.8M Q4 '23: -41.4M Q1 '24: -40.2M Q2 '24: -40.9M Q3 '24: -43M Q4 '24: -45.4M Q1 '25: -48.9M Q2 '25: -51M Q3 '25: -50.4M Q4 '25: -45.9M Q1 '26: -44.8M Q2 '26: -40.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 700K 1.4M 2.1M Q2 '15: 271.9K Q3 '15: 445.4K Q4 '15: 629.2K Q1 '16: 762K Q2 '16: 1.1M Q3 '16: 1.3M Q4 '16: 1.7M Q1 '17: 2M Q2 '17: 2M Q3 '17: 2M Q4 '17: 1.8M Q1 '18: 1.6M Q2 '18: 1.4M Q3 '18: 981K Q4 '18: 597.5K Q1 '19: 231.1K Q2 '19: 26.7K Q3 '19: 0 Q4 '19: 0 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -20.8M Q4 '21: -23M Q1 '22: -27.4M Q2 '22: -29.8M Q3 '22: -31.8M Q4 '22: -33.8M Q1 '23: -32.2M Q2 '23: -32.7M Q3 '23: -33.1M Q4 '23: -30.9M Q1 '24: -30M Q2 '24: -32.1M Q3 '24: -34.6M Q4 '24: -37.7M Q1 '25: -42.7M Q2 '25: -41.8M Q3 '25: -42.2M Q4 '25: -37.9M Q1 '26: -37.4M Q2 '26: -40.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q1 '20: -13.3M Q2 '20: -14.2M Q3 '20: -14.6M Q4 '20: -16.5M Q1 '21: -19M Q2 '21: -19M Q3 '21: -20.9M Q4 '21: -23.2M Q1 '22: -27.8M Q2 '22: -30.5M Q3 '22: -32.9M Q4 '22: -34.8M Q1 '23: -33.1M Q2 '23: -33.4M Q3 '23: -33.8M Q4 '23: -31.5M Q1 '24: -30.6M Q2 '24: -32.5M Q3 '24: -34.7M Q4 '24: -37.8M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '19: 5.8M Q2 '20: 14.5M Q3 '20: 23.3M Q1 '21: 37.2M Q2 '21: 38.8M Q3 '21: 39.6M Q1 '22: 43.2M Q2 '22: 43.3M Q3 '22: 43.3M Q1 '23: 44.7M Q2 '23: 44.7M Q3 '23: 44.7M Q1 '24: 44.7M Q2 '24: 44.8M Q3 '24: 46.9M Q1 '25: 66.5M Q2 '25: 66.5M Q3 '25: 66.9M Q1 '26: 68.3M Q2 '26: 68.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '21: -0.56 Q4 '21: -0.72 Q1 '22: -0.83 Q2 '22: -0.90 Q3 '22: -0.93 Q4 '22: -0.89 Q1 '23: -0.89 Q2 '23: -0.90 Q3 '23: -0.92 Q4 '23: -0.93 Q1 '24: -0.90 Q2 '24: -0.91 Q3 '24: -0.94 Q4 '24: -0.94 Q1 '25: -0.92 Q2 '25: -0.87 Q3 '25: -0.79 Q4 '25: -0.69 Q1 '26: -0.67 Q2 '26: -0.60 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.